Idience
NRDO company specializing in the development of new anticancer drugs
General Info.
| Company name | Idience Inc. |
|---|---|
| CEO | Lee, Wonsik |
| Foundation | May 24, 2019 |
| Address | 2, Baumoe-ro 27-gil, Seocho-gu, Seoul |
| Main business | R&D and commercialization of innovative anticancer drugs |
Major History
2019.08
Acquired patent right of new molecule entity IDX-1197
2019.11
Initiated Phase 1B/2A basket trial (Korea)
2020.12
Venadaparib phase 1A/1B Gastric cancer IND approved (US)
2021.01
Venadaparib phase 1A/1B Gastric cancer IND approved (KOR)
2021.03
Established US subsidiary (IDIENCE INC)
2021.12
Venadaparib phase 1A/1B Gastric cancer IND approved (CHN)
2022.05
Venadaparib phase 1A/1B basket trial IND approved (US)
2022.08
US FDA orphan drug designation for Venadaparib(Gastric cancer treatment)
2022.12
Pan-KRAS, LIN28, KRAS G12D Joint development agreement with Ildong Pharmaceutical
Pipelines
| Code | Venadaparib | ID11916 |
|---|---|---|
| Target | PARP inhibitor | 4th-generation Antiandrogen |
| Expected indicator | Gastric cancer Breast cancer Ovarian cancer |
mCRPC TNBC |
| Stage | Phase 1b/2a | NME |
| Features | Best-In-Class | First-In-Class |
NRDO: No Research Development Only
mCRPC: metastatic castration-resistant
prostate cancer
TNBC: triple-negative breast cancer
NME: new molecular entity
HCC:
hepatocellular carcinoma
Development Strategies
- Translational research approach: Organic linkage between basic and clinical research results
- Focus on development pipelines with very high market value and unmet demand
- Focus on low-molecular compounds, validated concepts and biomarkers that can increase the likelihood of development success
- Innovative clinical design to accelerate development and achieve early market access
